The trend towards outsourced buffer manufacturing in biopharmaceuticals

Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.

Buffers, the compounds or compound mixtures used to control pH in drug manufacturing, are a vital component to maintain the stability of both small molecule and biologic drugs during production and in their final form. Today, with rising interest in cell and gene therapies (CGTs) for diseases ranging from cancer to inherited diseases, and the growing need for the manufacturing of vaccines, biopharmaceutical companies are increasingly looking to outsource the development and production of buffers for both their drug development programs and therapeutics manufacturing.

Whether constrained by physical space, requirements for higher titers, lack of resources, or a preference for lean operations, the economics of make-v-buy when it comes to buffers is leaning to buy. Growth in CGT, as well as changes in the small molecule market, have made the production and use of buffers more specialized and more challenging. As a result, large and small biopharmaceutical companies alike are increasingly relying on third parties to source their buffers.

Key learning points: 

The growth of the biopharma marketThe challenges this growth bringsWhy are companies outsourcing?The benefits of outsourcingFuture development

Register your place now


Kate Buggle, Sales Director, Biopharma Europe

Kate Buggle is the Strategic Business Development Director for Actylis’ European Biopharmaceutical division. A biochemist educated at University College Dublin (BSc) and National University of Ireland, Galway (MSc), she has spent 20+ years in specialty chemicals and biopharmaceutical buffer sales, marketing, and customer support roles, including six years at Merck KGaA, Darmstadt, and 16 at SAFC. 



Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

When will the webinar take place? 

9 May 2024 at 3.00pm BST

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

What are the benefits of attending live? 

You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session. 

How long will the webinar be? 

This webinar will last up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.


Do you want to create an account?


Enter your email and password for European Pharmaceutical Review below.

I’ve forgotten my password

Step 1 – Create an account

By creating an account you’ll be able to register for this webinar, plus you’ll be able to access all of our member-only website content, printed or digital journal and emails.

Please enter your email and choose a password for your account. Passwords must include at least 8 characters, a mixture of both uppercase and lowercase letters, at least one letter and number and at least one special character, e.g. ! @ # ? ]





Step 2 – Subscription options

Please select whether you would like to receive European Pharmaceutical Review’s journal in printed and/or digital form, and choose which types of email communication you would like to receive.

Tick all that apply:

Step 3 – Personal details

Please enter your details.

Step 4 – Location details

Please enter your location details. We may use these details to personalise the content you see.

Step 5 – Areas of interest

Please select your areas of interest. We may use these details to personalise the content you see.

Tick all that apply:

Step 6 –


Tick all that apply:

I would like to receive relevant information and insights from the sponsor of this webinar, Actylis.

Email preferences

Please select which types of emails you would like to receive from European Pharmaceutical Review:

Privacy policy / terms & conditions

Please review and accept European Pharmaceutical Review’s privacy policy and terms & conditions



are you a developer?

  • Proven International Track Record
  • Vertically Integrated Federal Funds
  • Vertically Integrated Tax Credits
  • Vertically Integrated Investors
  • Vertically Integrated Lenders
  • Vertically Integrated Contractors